You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 18, 2024

Claims for Patent: 9,079,953

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,079,953

Title:	Anti-VEGF antibodies and their uses
Abstract:	The present disclosure relates to antibodies directed to vascular endothelial growth factor (\"VEGF\") and uses of such antibodies, for example to treat diseases associated with the activity and/or overproduction of VEGF.
Inventor(s):	Harding; Fiona A. (Santa Clara, CA), Akamatsu; Yoshiko (Palo Alto, CA), DuBridge; Robert B. (Belmont, CA), Powers; David B. (Fairfax, CA)
Assignee:	AbbVie Biotherapeutics Inc. (Redwood City, CA)
Application Number:	12/817,800
Patent Claims:	1. A monoclonal antibody or a binding fragment thereof which: (a) specifically binds to human VEGF; (b) comprises a heavy chain amino acid sequence having at least 95% sequence identity to SEQ ID NO:1 and a light chain amino acid sequence having at least 95% sequence identity to SEQ ID NO:2; and (c) has at least one amino acid substitution or combination of amino acid substitutions selected from: (i) K64S in CDR-H2; (ii) H97E and Y98F in CDR-H3; (iii) N31F in CDR-H1, H97D in CDR-H3, Y99D in CDR-H3, and S100aG in CDR-H3; (iv) N31F in CDR-H1, H97P in CDR-H3, Y99D in CDR-H3, and S100aG in CDR-H3; (v) N31F in CDR-H1, H97P in CDR-H3, and Y99E in CDR-H3; (vi) N31F in CDR-H1, H97E in CDR-H3, and Y99E in CDR-H3; (vii) N31F in CDR-H1, H97D in CDR-H3, and Y99E in CDR-H3; (viii) N31F in CDR-H1, H97E in CDR-H3, Y99D in CDR-H3, and S100aG in CDR-H3; (ix) N31F in CDR-H1, Y99D in CDR-H3, and S100aG in CDR-H3; (x) N31F in CDR-H1, H97P in CDR-H3, and Y99D in CDR-H3; (xi) N31F in CDR-H1, H97D in CDR-H3, and S100aG in CDR-H3; (xii) N31F in CDR-H1 and S100aG in CDR-H3; (xiii) N31F in CDR-H1, H97P in CDR-H3, and S100aG in CDR-H3; and (xiv) N31F in CDR-H1; wherein the substitutions occur at positions corresponding to Kabat numbering in the heavy chain of SEQ ID NO: 1 wherein the antibody or binding fragment thereof reduced immunogenicity or increased affinity to VEGF as compared to bevacizumab or ranibizumab. 2. The monoclonal antibody or binding fragment of claim 1, wherein the heavy chain amino acid sequence has at least 98% sequence identity to SEQ ID NO:1 and the light chain amino acid sequence has at least 98% sequence identity to SEQ ID NO:2. 3. The monoclonal antibody or binding fragment of claim 1, wherein the heavy chain amino acid sequence has at least 99% sequence identity to SEQ ID NO:1 and the light chain amino acid sequence has at least 99% sequence identity to SEQ ID NO:2. 4. The monoclonal antibody or binding thereof fragment of claim 1, wherein said amino acid substitution includes the substitution K64S. 5. The monoclonal antibody or binding thereof fragment of claim 1, wherein said amino acid substitution includes the substitution N31F. 6. The monoclonal antibody or binding thereof fragment of claim 1, wherein said amino acid substitutions include the substitutions H97E and Y98F. 7. The monoclonal antibody or binding fragment thereof of claim 1, wherein the antibody or binding fragment thereof is human or humanized antibody. 8. The monoclonal antibody or binding fragment thereof of claim 1, wherein the antibody is an IgG. 9. The monoclonal antibody or binding fragment thereof of claim 1, wherein the antibody or binding fragment thereof has the heavy chain framework sequences of the V.sub.H sequence of SEQ ID NO:1 and the light chain framework sequences of the V.sub.L sequence of SEQ ID NO:2. 10. The monoclonal antibody or binding fragment thereof of claim 1, wherein the antibody or binding fragment thereof has the heavy chain framework sequences of the V.sub.H sequence of SEQ ID NO:9 and the light chain framework sequences of the V.sub.L sequence of SEQ ID NO:10. 11. An antibody-drug conjugate comprising the anti-VEGF antibody or anti-VEGF binding fragment according to claim 1.

Details for Patent 9,079,953

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004	⤷ Try a Trial	2029-06-17
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	06/30/2006	⤷ Try a Trial	2029-06-17
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	08/10/2012	⤷ Try a Trial	2029-06-17
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	10/13/2016	⤷ Try a Trial	2029-06-17
Genentech, Inc.	LUCENTIS	ranibizumab	Injection	125156	03/20/2018	⤷ Try a Trial	2029-06-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.